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To the Editor: Two recent articles have reported the burden
of vitamin D deficiency in patients with chronic kidney
disease (CKD).1,2 We would like to highlight the increased
risk in patients of SE Asian origin, an ethnic group known to
be at risk of hypovitaminosis D due to diet and lack of
sunlight exposure.3 We have measured circulating vitamin D
and markers of bone metabolism in 113 prevalent stage 3 and
stage 4 patients (60 Caucasians and 53 SE Asians). SE Asians
were younger than Caucasians (68±13 vs 63±13 years,
P¼ 0.025). Seventy-seven of the patients were men, and 30
had diabetes mellitus, which was predictably more prevalent
in SE Asians (40 vs 15%, w2-test P¼ 0.003). Fifty-two patients
had CKD 3 and 61 patients had CKD 4. Calcium, phosphate,
and alkaline phosphatase were not different between groups
(CKD or ethnicity). 25(OH)D3 was not different between
CKD3 and 4 (15.9±9.6 vs 15.3±8.9 ng ml1, P¼NS). SE
Asians had lower 25(OH)D3 than Caucasians (10.3±6.4 vs
20.3±8.7 ng ml1, Po0.001) (Figure 1). 25(OH)D3 was
below the level of detection in nine patients, all SE Asians—
four with CKD 3 and five with CKD 4. No difference was
found in mean parathyroid hormone levels between races. An
increase in parathyroid hormone was observed with worsen-
ing stage of CKD (10±8 vs 15±11 pmol l1 CKD 3 vs CKD
4, P¼ 0.01). A decrease in 25(OH)D3 was associated with an
increase in parathyroid hormone (Pearson’s r¼0.27,
P¼ 0.01). Rising parathyroid hormone predictably correlated
with a decreasing estimated glomerular filtration rate
(Pearson’s r¼0.34, P¼ 0.001). Larger studies are needed
to investigate the benefits of replacement of vitamin D at
physiological doses in CKD patients of different ethnic
groups.
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The letter to the editor from Kosmadakis et al.1 references
our findings of 25-hydroxyvitamin D (25OHD) levels in
the National Health Examination Survey (NHANES III).2
In their subjects, no significant differences in 25OHD
levels between stage III and IV chronic kidney disease
(CKD) were observed, although both levels were consistent
with 25OHD insufficiency.3 These findings are contrary to
what was observed in NHANES III where the major decline
in 25OHD was observed in stage IV CKD.
In response, we would like to point out potential reasons
for these differences in their study compared with NHANES
III which include (1) a small number of subjects with CKD
stage III (52 vs 854), (2) the lack of adjustment of 25OHD
levels with leisure physical activity as an indirect measure-
ment of sunlight exposure, and (3) the high preva-
lence of diabetes. Although no information is provided
regarding urinary protein excretion, it is likely that their
stage III and IV CKD diabetic patients had some degree of
proteinuria. This could explain the lower values of 25OHD
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Figure 1 | 25(OH)D3 levels vs ethnicity (Po0.001).
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in their cohort as greater urinary levels of vitamin D
metabolites have been observed in patients with abnormal
urinary protein excretion.4 Of note, Ishimura et al.5
reported, in 76 Japanese patients with CKD stage III and
IV, that diabetic patients had lower 25OHD levels than non-
diabetic (11.4±5.6 ng ml1 vs 22.3±9.4 ng ml1; Po0.0001).
Larger representative studies are necessary to evaluate the
prevalence of 25OHD deficiency across different ethnics
groups and levels of kidney dysfunction.
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Kosmadakis and co-workers have submitted a letter to
Kidney International that describes the results of a prevalent
cohort of 113 South East Asians and Caucasians with
chronic kidney disease 3 and 4. They describe in that cohort
a deficiency of 25 Vitamin D that is associated with hyper-
parathyroidism.1 As these data are essentially presented in
abstract form, as a letter, it is difficult to comment in detail.
The issue of ethnicity and Vitamin D levels is important
given the differential cardiovascular and bone disease
risks, which have been described in chronic kidney disease
in different ethnic groups. This short letter to the editor
does highlight the issue of ethnicity for the readership.
The SEEK paper2 reported results on a large cohort, which
included a substantial cohort of African Americans.
Differences in that cohort were also described, but were
not the major focus of the paper.
Of note, two manuscripts have been submitted, one from
the SEEK (US) database and one from a different Canadian
provincial database, which further address the issue of
ethnicity and differences in prevalence of abnormalities of
mineral metabolism. Together, these reports, including the
letter from these authors, suggest that the international
community need to review data in the context of ethnicity
so as to ensure robust conclusions and appropriate design of
therapeutic trials.
Larger studies are needed to investigate these asso-
ciations and their implications in chronic kidney disease
patients. The data to data differences are interesting and
suggestive, but a substantial amount of further research, in
both epidemiology and pathophysiology, is needed before
one advocates for large-scale therapeutic interventional
trials based on observations of single deficiencies.
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To the Editor: Lee et al.1 recently addressed the implications
for diabetic tubulopathy of reduced sodium-dependent
glucose transport across the proximal tubule brush border
membrane (BBM) during hyperglycemia. We believe that the
discussion gives an incomplete view of how BBM glucose
transport is influenced by diabetes mellitus.
Our own studies have failed to detect changes in sodium-
dependent glucose transport-mediated glucose uptake across
the BBM during experimental diabetes mellitus.2 Interestingly,
however, we found that diabetes promoted facilitated
(facilitated glucose transports (GLUT)-mediated) glucose
uptake across this membrane,2 this being largely due to an
eightfold increased BBM expression of GLUT2. Normalization
of plasma glucose reduced GLUT-mediated uptake and
GLUT2 expression to non-diabetic levels. Additional work3
implies that increased BBM levels of protein kinase C-b1
isoform may be involved in the diabetes-induced appearance
of GLUT2 at the BBM. Indeed, we found strong positive linear
correlations between plasma glucose level (5–40 mmol/l) and
BBM expression of both GLUT2 and protein kinase C-b1 and
between GLUT2 and protein kinase C-b1.
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